JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Inclusion criteria

• Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Must be able to provide an archived tumor sample
• Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor
• Dose Expansion phase cohorts must meet specific expression or gene mutation where indicated
• Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition
• Must have at least 1 measurable lesion per RECIST v1.1
• Must have adequate organ functions
• Must be able to swallow and retain orally administered medication

Exclusion criteria

• Has central nervous system (CNS) metastases or carcinomatous meningitis, except if CNS metastases treated and no evidence of radiographic progression or hemorrhage for at least 28 days
• Active infection requiring systemic treatment within 7 days
• Active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV
• Any severe and/or uncontrolled medical conditions
• left ventricular ejection fraction (LVEF) ≤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA)
• QT interval using Fridericia's formula (QTcF) interval \>470 msec
• Experiencing unresolved CTCAE 5.0 Grade \>1 toxicities
• Clinically significant eye disorders